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Objective: Atopic dermatitis (AD) is a chronic inﬂammatory disease causing intense pruritus,
and with typical clinical features. There are few epidemiological studies concerning AD in
adults, aswell as little information about its prognostic. The aimof this studywas to evaluate
the clinical and epidemiological course of adults with AD.
Methods: 80 patients aged above 18 years (mean age=29 years) were selected (30 males and
50 females) and interviewedabouthospitalization, systemic corticoidusage, age ofADonset,
and personal and/or familial history of atopy. Disease severity was evaluated through the
Scoring Atopic Dermatitis (SCORAD) tool. Laboratory examination included IgE serum levels
and eosinophil blood count.
Results: 71 out of 80patients referred associationwith respiratory symptoms (18hadasthma,
17 had rhinitis, and 36 had both conditions); nine out of 80 patients denied any respiratory
disease. AD patients were divided in mild (n=25), moderate (n=30), and severe (n=25); 56%
had one or more hospitalizations due to AD. A positive association was found between IgE
serum levels, eosinophil blood count, and disease severity.
Conclusion: Adult AD represents a clinical challenge that needs to be better characterized,
since it can be misdiagnosed and interferes with the patient’s social and personal life. The
association of skin and respiratory atopic disease is frequent, and laboratory parameters
such as circulating IgE levels and eosinophil blood count may be helpful to assess disease
severity.
© 2013 Elsevier Editora Ltda.
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Objetivo: Dermatite atópica (DA) é uma doenc¸a inﬂamatória crônica com prurido intenso
e características clínicas típicas. Há poucos estudos epidemiológicos a respeito da DA em
adultos, bem como pouca informac¸ão disponível sobre o seu prognóstico. O objetivo do
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presente estudo é avaliar as características clínicas e o curso epidemiológico dos adultos
com DA.
Métodos: Foram selecionados 80 pacientes com idade acima de 18 anos (média de idade=29
anos, 30 homens e 50 mulheres), que foram entrevistados sobre: internac¸ões, uso de cor-
ticóide sistêmico, idade de início da DA, história pessoal e/ou familiar de atopia. A gravidade
da doenc¸a foi avaliada de acordo com o SCORing Atopic Dermatitis (SCORAD). A avaliac¸ão
laboratorial incluiu dosagem sérica de IgE e contagem sanguínea de eosinóﬁlos.
Resultados: 71 dos 80 pacientes referiram associac¸ão com sintomas respiratórios (18: asma,
17: rinite alérgica e 36: ambas as condic¸ões); nove dos 80 indivíduos negaram qualquer
sintoma respiratório. Os pacientes com DA foram divididos em DA leve (n=25), moderada
(n=30) e grave (n=25); destes, 56% tiveram uma ou mais internac¸ões por conta da doenc¸a.
Veriﬁcou-se uma associac¸ão entre níveis séricos de IgE, contagem sanguínea de eosinóﬁlos
e gravidade da doenc¸a.
Conclusão: A DA do adulto representa um desaﬁo clínico que necessita ser melhor caracter-
izado, uma vez que pode ser erroneamente diagnosticada, e interfere diretamente na vida
social e pessoal dos pacientes. A associac¸ão entre manifestac¸ão respiratória e cutânea é
frequente, e parâmetros laboratoriais como níveis de IgE circulante e contagem sanguínea
de eosinóﬁlos podem ser úteis para acompanhar a gravidade e evoluc¸ão da doenc¸a.
Introduction
Atopic dermatitis (AD) is a pruritic, chronic, and inﬂammatory
disease, with typical clinical features. AD is one of the most
common skin diseases, with a prevalence of 10% to 20% in
children and 1% to 3% in adults.1,2 Diagnosis is based on clin-
ical ﬁndings,3 and despite the existence of a wide number of
disease outcome measures, three scores (EASI, Scoring Atopic
Dermatitis [SCORAD], and POEM) have been adopted by the
majority of the studies.4–8
In 30% to 50% of the AD patients, the disease markedly
improves during elementary school-age or adolescence.
Among those, ADpatients that present the disease until adult-
hood, 50% to 60% persist with a chronic, recurrent course.9
The pathogenesis of AD remains complex. Gene-environ-
ment interactions in genetically predisposed individuals play
a central role.10 Moreover, there is a variability of systemic and
skin immune abnormalities in AD, such as increased serum
IgE and allergen sensitization, abnormalities in epidermal bar-
rier (gene mutations encoding proteins such as ﬁlaggrin), the
Th1/Th2 paradigm, and microbe skin colonization.1,10,11
The skin barrier function has been considered a protective
factor against the development of AD, since inherited abnor-
malities in critical epidermal proteins have been identiﬁed in
recent studies of AD patients. One of these proteins is ﬁlag-
grin (FLG), a granular cell layer key protein that is processed
from proﬁlaggrin and facilitates terminal differentiation of
the epidermis.12 FLG is responsible for the aggregation of ker-
atin ﬁlaments, which collapse the granular cells into nuclear
squames to form the corniﬁed cell envelope of the stratum
corneum (SC) and the skin barrier, protecting the organ-
ism against environmental agents and preventing epidermal
water loss.13–15 Skin barrier defects caused by FLG mutations
allows the penetration of allergens through the epidermis
and their interaction with antigen-presenting cells, leading to
the development of atopic disorders, including asthma and
rhinitis.16 Recent studies demonstrated that FLG mutations
are strongly associatedwith increased atopic eczema risk, and
probably account for approximately 10% of cases in Europe.17
ADhas been classiﬁed into two groups: extrinsic form (clas-
sic IgE-mediated allergic) and intrinsic form (non-allergic).18
FLG mutations have also been linked to extrinsic AD in recent
studies, indicating that high IgE serum levels may correlate
with disease severity and skin barrier defects.19
Recent literature suggests that circulating eosinophil
counts could be used as a diagnostic tool to differentiate
extrinsic from intrinsic AD. Eosinophil blood count corre-
lates with disease severity, similar to circulating IgE levels.
Eosinophilia and eosinophil skin inﬁltration found in AD
patients link AD to cytokines recruitment, and chemokines
and eosinophil activation.20
In the skin, AD presents as a model of Th1/Th2 response
with a biphasic pattern: in acute lesions, a great number
of interleukin (IL)-4, IL-5, and IL-13 (Th2-type cytokines) are
found, whereas in chronic lesions there are high levels of
IL-5, IL-12, and IFN- (Th1 cells).1 Interleukin-4 and IL-13
are implicated in the initial phase of tissue inﬂammation,
and may mediate an isotype switching to IgE synthesis, and
up-regulation expression of adhesion molecules on endothe-
lial cells. IL-5 increases the survival of eosinophils, and
eosinophilia with an increase of the eosinophilic cationic pro-
tein (ECP) correlates to disease severity.21 Recently, regulatory
T-cells with immunosuppressant activity in AD, such as IL-17,
secreting Th17 cells and Th22 (IL-22 secreting cells) have been
investigated in several studies.10,22,23
Staphylococcus aureus is present in 80% to 100% of AD
skin, and is responsible for the disease relapsing course. S.
aureus exacerbates AD by secreting toxins and superantigens
which stimulate T cells and macrophages. Most AD patients
produce speciﬁc IgE antibodies against staphylococcal entero-
toxins that correlate with disease severity. Superantigens can
also induce corticosteroid resistance, suggesting that several
mechanisms are implied in triggering AD ﬂares.1,10,24,25
Little information is available regarding the prognosis of AD
adult patients. A monthly follow-up study was conducted in
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Fig. 1 – Clinical features of AD in adults. A. Facial involvement in atopic dermatitis-extensive licheniﬁcation of the front,
periorbital areas, and malar regions, sparing the central seborrheic areas. B. Severe AD, with erythema, xerosis,
and massive licheniﬁcation of the inferior limbs.
adults with AD for ten years, and showed that high levels of
circulating IgE and eosinophil counts as early as the ﬁrst visit
were indicative of persistent AD.26
This study aimed to evaluate adults diagnosed with AD,
with emphasis on their clinical and epidemiological course.
Methods
The patients were selected from the Atopic Dermatitis Out-
patient Clinic of the Department of Dermatology from the
Medical School of the Universidade de São Paulo, Brazil.
Between December, 2010 and April, 2011, 329 patients diag-
nosed with AD (according to Haniﬁn & Rajka’s criteria)3 were
evaluated; 115 were above the age of 18, and 80 of those agreed
to participate in the study after signing the informed consent
(approved by the Ethics Committee of the Medical School of
the Universidade de São Paulo). They were interviewed and
classiﬁed according to the SCORAD (5) (Fig. 1A and B).
All participants answered a questionnaire that included
data about their AD history, age of disease onset, use of sys-
temic corticosteroids or other immunosuppressant drugs (e.g.
methotrexate or cyclosporine), hospitalization, and personal
and/or familial history of atopy. All included patients were
using ﬁrst-line therapy for disease control (e.g. emollients and
topical corticosteroids).27 IgE serum levels were detected by
nephelometric method (N Latex IgE Mono, Dade Behring –
Marburg, Germany). Levels up to 100 IU/mL were considered
normal. Blood tests were performed to evaluate circulating
eosinophil counts (normal levels: 0.0% to 5.0%).
Statistical analysis
Mann-Whitney and Kruskal-Wallis non-parametric tests
were used to compare two or three sets of data, respec-
tively. Correlation between data was established using
Spearman’s- non-parametric correlation test. Difference
between groups was considered statistically signiﬁcant when
p-value ≤ 0.05.
Results
Demographic data included: 80 adults with AD, aged 18 or
older (ranging from 18 to 79 years, mean age 29), and gen-
der distribution: 30 males and 50 females. 71 of 80 AD patients
reported associationwith respiratory diseases (18 had asthma,
17 had rhinitis, and 36 had both conditions); nine denied any
respiratory illness. SCORAD ranged between 0 and 100, andAD
patients were classiﬁed as mild (n=25), moderate (n=30), and
severe (n=25). 56% of the AD patients (44/80) had one or more
hospitalizations during their life, showing the impact of the ill-
ness on their quality of life. Systemic corticosteroid usage, (but
not adjuvant oral immunosuppressant) such as cyclosporine
or methotrexate,27 was reported by 57 AD patients, and was
followed by ﬂares after tapering initial doses (Table 1).
Mean circulating IgE levels in AD patientswas 18,340 UI/mL
(Fig. 2A). There was an association of IgE levels and disease
severity (Fig. 2B). However, no relationship was found between
serum IgE levels and respiratory disease (Data not shown).
A positive correlation between eosinophil blood count and
disease severity SCORAD (Fig. 2C) was detected.
Discussion
AD is one of the most frequent dermatoses in the pediatric
population; approximately 40% of the patients persist with
the disease in adulthood. Although rare, the onset of AD may
occur in adults, usually after the third decade of life.28 Adult
AD is complex, and the disease affects personal and familial
dynamics.29,30
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Table 1 – Demographic data, hospitalization, systemic
corticoids usage, and disease severity in adults
with atopic dermatitis (AD).
Patients n=80
Gender (male/female) 30/50
Age (years) 18-79
Mean age 29
Age of disease onset (years)/n 0-2/19
3-11/21
Above 12/40
SCORAD (0-100) Mild – n=25
Moderate – n=30
Severe – n=25
AD and asthma n=18
AD and rhinitis n=17
AD, asthma, and rhinitis n=36
Hospitalization n=44
Systemic corticoids usage n=57
The present study aimed to characterize the proﬁle of AD in
adults,which corresponds to one-third of the total ADpatients
registered at this specialized unit. The association with respi-
ratory disease was present in 71/80 AD patients, and exclusive
dermatological involvement occurred in 9/80 patients. In a
national study from Taiwan, the concomitance of respiratory
involvement with AD was approximately 50%.28
Regarding demographic features, gender differences in AD
vary in several studies.31,32 Gender, however, does not appear
to be a relevant marker of AD in adults. In the present study,
a prevalence of females was observed (63% females and 37%
males).
Hospitalization was a relevant item in the applied ques-
tionnaire. It was present in 56% of the interviewed patients,
and reﬂected how AD impacts the patient’s and family’s qual-
ity of life. Interestingly, it differs from other centers, where
hospitalization reaches less than 0.2%, and occurs due to
complications from infectious diseases associated to AD.31
Another topic was the use of systemic steroids, not routinely
recommended for AD due to their side effects; 72% percent
of the present AD patients related use of systemic corticoids,
usually self-medicated.31
Circulating IgE levels are usually elevated in the majority of
AD patients, and are reported to be associated with allergen-
speciﬁc IgE status.18 In the present subjects, only one of 80
patients showed normal serum levels (up to 100 UI/mL), in
contrast to the majority of patients, who presented an aver-
age IgE serum level of 18,340 UI/mL. The present data are in
agreement with the literature, which shows that the majority
of AD patients have high IgE levels, in a clear predominance
of the extrinsic pattern. Moreover, IgE serum levels correlate
with disease severity, suggesting that physicians should ded-
icate great care to patients with elevated IgE serum levels,
reinforcing education and compliance.26
Unfortunately, so far there are no speciﬁc laboratory
markers to evaluate AD severity, but high IgE serum lev-
els and eosinophil blood count are frequently found in AD
patients. Some studies consider that a future perspective in
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Fig. 2 – Evaluation of IgE, eosinophils and disease severity. A. Total IgE serum levels in AD patients. B. IgE serum levels of
AD patients distributed according to disease severity. Line represents mean of IgE secretion expressed in UI/mL. C. Positive
correlation between eosinophils blood count and disease severity. *p ≤ 0.05; **p ≤ 0.005; ***p ≤ 0.0005.
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the treatment of AD may be based on serological markers
such as IL-4.21 Some studies suggest that eosinophil blood
countmay be used as an indicator to distinguish intrinsic from
extrinsic forms of AD, and others show that eosinophil blood
count correlates with both disease severity and IgE serum
levels.24 All AD patients included in the present study showed
high eosinophil blood counts (mean value=9.45%; normal lev-
els = 0% to 5%). A positive correlation between eosinophils and
disease severity was found (p=0.0024; r = 0.3620), but no cor-
relation between IgE serum levels and eosinophil blood count
was detected.
In conclusion, the present study presented an elevated
number of adults with AD in this clinic, indicating that a care-
ful follow-up, together with an education strategy are needed,
since this is a chronic and high-cost disease with expressive
social and economic implications. IgE serum levels and/or
eosinophil blood counts present a positive correlation with
disease severity, and are relevant parameters for managing
this difﬁcult and chronic disease, contributing to new strate-
gies of treatment.
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